Furthermore, there is evidence for crosstalk between integrin and EGFR signaling in both breast [38] and lung cancer [39], suggesting that successful targeting of these pathways in preM ER+ breast cancer may require a multi-pronged approach. This evidence concerns the gene ESR1 and lung cancer.